TD Cowen Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $500
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Phil Nadeau maintains a Buy rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and raises the price target from $450 to $500.
July 23, 2024 | 5:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TD Cowen analyst Phil Nadeau maintains a Buy rating on Vertex Pharmaceuticals and raises the price target from $450 to $500.
The raised price target and maintained Buy rating from a reputable analyst can positively influence investor sentiment and potentially drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100